Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- 1 February 2008
- journal article
- research article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 6 (5), 545-555
- https://doi.org/10.1016/j.cgh.2007.12.015
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Association Between Unreported Outcomes and Effect Size Estimates in Cochrane Meta-analysesJAMA, 2007
- Is there an experimental basis for the development of ischaemic colitis as a result of 5‐HT3 antagonist treatment?Neurogastroenterology & Motility, 2006
- Evidence based medicine - The case of the misleading funnel plotBMJ, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trialBritish Journal of Clinical Pharmacology, 2000
- The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised ratGut, 2000
- Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsAlimentary Pharmacology & Therapeutics, 1999
- Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonistAlimentary Pharmacology & Therapeutics, 1999
- A Double-Blind Placebo-Controlled Trial with Loperamide in Irritable Bowel SyndromeScandinavian Journal of Gastroenterology, 1996
- U. S. Householder survey of functional gastrointestinal disordersDigestive Diseases and Sciences, 1993